Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digoxin for Relapsed Non-WNT, Non-SHH Medulloblastoma
NCT06701812Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2026
- Primary completion
- Feb 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of digoxin in medulloblastoma, sponsored by Moffitt Cancer Center. Primary endpoint: Progression Free Survival at 4 months. Started Jan 2026; status: recruiting.
02
Drugs
digoxin
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT06701812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701812.